↧
Pfizer gets rights to sell insulin from Biocon
Pfizer Inc. said Monday it agreed to pay an initial $200 million to the Indian biotechnology company Biocon Ltd. for the right to sell several of its insulin products used in the treatment of diabetes....
View ArticleFinally, scientific proof that it’s not our fault
New diabetes research from Brookhaven National Laboratory.
View Article